Related Experiment Video

Updated: May 6, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.1K

Pyridoxine-dependent epilepsy due to antiquitin deficiency: achieving a favourable outcome

Renata Oliveira1, Cristina Pereira2, Fidjy Rodrigues1

  • 1Serviço de Genética Médica.

Epileptic Disorders : International Epilepsy Journal with Videotape
|November 5, 2013
PubMed

Insights

Pyridoxine-dependent epilepsy, a genetic disorder, can be effectively treated with pyridoxine. This study confirms urinary alpha-aminoadipic semialdehyde as a reliable biomarker for diagnosing this condition, even during treatment.

Area of Science:

  • Neurology
  • Biochemistry
  • Genetics

Background:

  • Pyridoxine-dependent epilepsy (PDE) is a rare genetic disorder.
  • Neonatal PDE presents with intractable seizures unresponsive to conventional antiepileptic drugs.
  • Early diagnosis and treatment with pyridoxine are crucial for favorable neurodevelopmental outcomes.

Purpose of the Study:

  • To report on four male patients with pyridoxine-dependent epilepsy.
  • To confirm the efficacy of pyridoxine treatment and identify reliable diagnostic biomarkers.
  • To analyze genetic mutations in the antiquitin gene.

Main Methods:

  • Clinical evaluation and medical record review of four PDE patients.
  • Biochemical analysis of urinary alpha-aminoadipic semialdehyde excretion.
  • Genetic analysis of the antiquitin gene (ALDH7A1).

Main Results:

  • All four patients achieved seizure freedom with pyridoxine treatment.
  • Elevated urinary alpha-aminoadipic semialdehyde was detected in all patients, serving as a reliable biomarker.
  • Genetic analysis revealed a large homozygous deletion in one patient and compound heterozygous mutations in two others.

Conclusions:

  • Pyridoxine treatment is highly effective for pyridoxine-dependent epilepsy.
  • Urinary alpha-aminoadipic semialdehyde is a dependable biomarker for PDE diagnosis, irrespective of pyridoxine treatment.
  • Genetic confirmation of antiquitin gene mutations aids in diagnosis and genetic counseling.

Keywords:
ALDH7A1pyridoxine-dependent epilepsyα-AASA

More Related Videos

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

11.3K
Pentylenetetrazole-Induced Kindling Mouse Model07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

34.2K

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K